{
  "query": "eli lilly",
  "ticker": "LLY",
  "start_date": "08-08-2025",
  "end_date": "22-08-2025",
  "backward_start_date": "20-07-2025",
  "backward_end_date": "07-08-2025",
  "prediction_window_days": 14,
  "max_backward_days": 19,
  "fetch_timestamp": "2026-02-21 20:27:22",
  "article_count": 48,
  "articles": [
    {
      "title": "Dow, S&P 500 end lower; Eli Lilly shares fall after drug data",
      "url": "https://finnhub.io/api/news?id=5b45a140738a0999843d636ba38052962ef077703513d1962205a0c130cfc1f2",
      "sourceurl": "https://finnhub.io/api/news?id=5b45a140738a0999843d636ba38052962ef077703513d1962205a0c130cfc1f2",
      "seendate": "20250807T221709Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "STORY: U.S. stocks ended mixed on Thursday, with the Dow dropping about half a percent, the S&P 500 closing essentially flat, and the Nasdaq ticking up about three-tenths of a percent.Investors digested a Bloomberg report early in the session that Fed Governor Christopher Waller was President Donald Trump's top candidate for central bank chair.Trump has been highly critical of current Chair Jerome Powell for holding off on cutting interest rates as the Fed weighs the potential inflationary effects of Trump's tariffs.Higher tariffs on imports from dozens of countries kicked in on Thursday, raising the average import duty to its highest in a century. And while we still have quite a bit of negotiating to do country by country, they are enacted. And so that is going to weigh on different aspects of the market, the supply chain, pricing. And so I think right now it's just, it's a lot of that digestion on, you know, how long are negotiations going to take for different countries? What will they look like in the end?”Stocks on the move Thursday included Eli Lilly, which plummeted more than 14% after data from its experimental weight-loss pill disappointed.Shares of cybersecurity firm Fortinet tumbled 22% after the company delivered a revenue forecast below Wall Street estimates.And shares of Pinterest climbed more than 12% in extended trading after the social media platform beat analysts' estimates for second-quarter revenue.Rapid growth among Gen Z users along with the platform's AI-powered marketing tools have made the company attractive to advertisers.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 7,
        "relevant_sentences": 6,
        "relevance_ratio": 0.8571,
        "condensed": false,
        "filter_action": "filtered"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.4418
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In",
      "url": "https://finnhub.io/api/news?id=ca08b038fdbc777853dfa8665e0d6d047a108ec398a5f4add2cbd6f301247f55",
      "sourceurl": "https://finnhub.io/api/news?id=ca08b038fdbc777853dfa8665e0d6d047a108ec398a5f4add2cbd6f301247f55",
      "seendate": "20250807T190448Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may simply want to hold for now.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3769
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging",
      "url": "https://finnhub.io/api/news?id=b14b892c37820f0ed51ee54b89ec2560e20e0a1a62ff4ddf00050577e0414909",
      "sourceurl": "https://finnhub.io/api/news?id=b14b892c37820f0ed51ee54b89ec2560e20e0a1a62ff4ddf00050577e0414909",
      "seendate": "20250807T163100Z",
      "domain": "MarketWatch",
      "language": "English",
      "content": "Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2722
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment",
      "url": "https://finnhub.io/api/news?id=8f363360378a2f7c97f0bed1a19e3711ea97fe2d3356e9116b4bdb6536cd4f4d",
      "sourceurl": "https://finnhub.io/api/news?id=8f363360378a2f7c97f0bed1a19e3711ea97fe2d3356e9116b4bdb6536cd4f4d",
      "seendate": "20250807T131431Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY may be a buying opportunity.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3839
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly and Company 2025 Q2 - Results - Earnings Call Presentation",
      "url": "https://finnhub.io/api/news?id=80d85f845aa5aa3e9c912cc5e6762c0170c52f689deb1a6c4f49ea7acbd390ca",
      "sourceurl": "https://finnhub.io/api/news?id=80d85f845aa5aa3e9c912cc5e6762c0170c52f689deb1a6c4f49ea7acbd390ca",
      "seendate": "20250807T122940Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "The following slide deck was published by Eli Lilly and Company in conjunction with their 2025 Q2 earnings call.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2931
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm",
      "url": "https://finnhub.io/api/news?id=f438c6d83a65f7d629d1cca2f50527934ca6c3f52b4bd0f5478688aaf5c75aa4",
      "sourceurl": "https://finnhub.io/api/news?id=f438c6d83a65f7d629d1cca2f50527934ca6c3f52b4bd0f5478688aaf5c75aa4",
      "seendate": "20250807T122000Z",
      "domain": "DowJones",
      "language": "English",
      "content": "Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3322
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates",
      "url": "https://finnhub.io/api/news?id=e8f175b2f6387f2adc96bb9b12b3d9073f1c469c333e8d99a1ccb5d6d8579467",
      "sourceurl": "https://finnhub.io/api/news?id=e8f175b2f6387f2adc96bb9b12b3d9073f1c469c333e8d99a1ccb5d6d8579467",
      "seendate": "20250807T115502Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Lilly (LLY) delivered earnings and revenue surprises of +12.48% and +5.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.291
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly Stock Dives Drops After Earnings Beat. Here’s Why.",
      "url": "https://finnhub.io/api/news?id=7f9a172e215b9bf2d327265754e8bd50efbe959ab318dae915451d257e6de50e",
      "sourceurl": "https://finnhub.io/api/news?id=7f9a172e215b9bf2d327265754e8bd50efbe959ab318dae915451d257e6de50e",
      "seendate": "20250807T113800Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday. The medicine, Orforglipron, resulted in a weight reduction of on average 12.4% over 72 weeks in adults with obesity, Lilly said in a statement. Adjusted earnings per share (EPS) came in at $6.31 on sales of $15.6 billion in the quarter, beating expectations of $5.60 a share on sales of $14.7 billion, according to FactSet.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3242
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results",
      "url": "https://finnhub.io/api/news?id=7ac127bc2dc9ae144d21a8ceaa0d91a5b41459e1c2e56151d521aa40623f47a8",
      "sourceurl": "https://finnhub.io/api/news?id=7ac127bc2dc9ae144d21a8ceaa0d91a5b41459e1c2e56151d521aa40623f47a8",
      "seendate": "20250807T110130Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall Street.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3354
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again.",
      "url": "https://finnhub.io/api/news?id=97839baeeadcfe7bd00cc854258552ad7ae2bd0a650866787c9d7d26516dbe18",
      "sourceurl": "https://finnhub.io/api/news?id=97839baeeadcfe7bd00cc854258552ad7ae2bd0a650866787c9d7d26516dbe18",
      "seendate": "20250807T102400Z",
      "domain": "MarketWatch",
      "language": "English",
      "content": "Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 1,
        "relevance_ratio": 0.5,
        "condensed": false,
        "filter_action": "filtered"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3023
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly: targets raised for 2025",
      "url": "https://finnhub.io/api/news?id=5799b352e43055b863f2451a262abff4031f26ef2688bd9a6735fa166f3daf7b",
      "sourceurl": "https://finnhub.io/api/news?id=5799b352e43055b863f2451a262abff4031f26ef2688bd9a6735fa166f3daf7b",
      "seendate": "20250807T080526Z",
      "domain": "Finnhub",
      "language": "English",
      "content": "In its quarterly report, Eli Lilly said that it is raising its adjusted EPS target range for FY 2025 to between $21.75 and $23, up from a previous forecast of $20.78 to $22.28. However, NB: after...",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2915
      },
      "impact_horizon_weight": 0.9898,
      "final_weight": 0.9734
    },
    {
      "title": "Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday",
      "url": "https://finnhub.io/api/news?id=45221b3e09e5284f7727eea3d374b03be681c9a917f8b2520d67597b2d90dc9b",
      "sourceurl": "https://finnhub.io/api/news?id=45221b3e09e5284f7727eea3d374b03be681c9a917f8b2520d67597b2d90dc9b",
      "seendate": "20250806T203400Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage in the booming weight-loss drug market. Competitor Novo Nordisk has fallen behind Lilly, as Lilly’s weight-loss shot Zepbound has seized a commanding majority of U.S. obesity prescriptions over Novo’s Wegovy. On Wednesday, Novo Nordisk presented data showing that Zepbound now accounts for 59% of U.S.-branded weight-loss prescriptions, while Wegovy has just 40%.",
      "coverage_count": 1,
      "days_ago": 2,
      "recency_weight": 0.9163710743801653,
      "content_stats": {
        "total_sentences": 4,
        "relevant_sentences": 4,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.276
      },
      "impact_horizon_weight": 0.96,
      "final_weight": 0.9379
    },
    {
      "title": "RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program",
      "url": "https://finnhub.io/api/news?id=05308f599c76e6dae037fbd01f0814a3dade54177321bbb9693346fe85166cf9",
      "sourceurl": "https://finnhub.io/api/news?id=05308f599c76e6dae037fbd01f0814a3dade54177321bbb9693346fe85166cf9",
      "seendate": "20250806T114923Z",
      "domain": "Benzinga",
      "language": "English",
      "content": "Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.",
      "coverage_count": 1,
      "days_ago": 2,
      "recency_weight": 0.9163710743801653,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.302
      },
      "impact_horizon_weight": 0.96,
      "final_weight": 0.9379
    },
    {
      "title": "Is Wall Street Bullish or Bearish on Eli Lilly Stock?",
      "url": "https://finnhub.io/api/news?id=afb4c0660855c5fb7ec9134a68cdcc3b5bbc1eba11ec8281139f136d562e8439",
      "sourceurl": "https://finnhub.io/api/news?id=afb4c0660855c5fb7ec9134a68cdcc3b5bbc1eba11ec8281139f136d562e8439",
      "seendate": "20250806T094837Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.",
      "coverage_count": 1,
      "days_ago": 2,
      "recency_weight": 0.9163710743801653,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.299
      },
      "impact_horizon_weight": 0.96,
      "final_weight": 0.9379
    },
    {
      "title": "Eli Lilly Earnings: What To Look For From LLY",
      "url": "https://finnhub.io/api/news?id=9fcf50429442e6073940779db3ecdd7c7db049a917a291450985abdf7af82623",
      "sourceurl": "https://finnhub.io/api/news?id=9fcf50429442e6073940779db3ecdd7c7db049a917a291450985abdf7af82623",
      "seendate": "20250806T031921Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what investors should know.",
      "coverage_count": 1,
      "days_ago": 2,
      "recency_weight": 0.9163710743801653,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2782
      },
      "impact_horizon_weight": 0.96,
      "final_weight": 0.9379
    },
    {
      "title": "Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance",
      "url": "https://finnhub.io/api/news?id=71b4ba9d94d300711fa16bdcd3e427a8d25ad41eb657fe4e4037f4d9562a5a70",
      "sourceurl": "https://finnhub.io/api/news?id=71b4ba9d94d300711fa16bdcd3e427a8d25ad41eb657fe4e4037f4d9562a5a70",
      "seendate": "20250805T162217Z",
      "domain": "DowJones",
      "language": "English",
      "content": "Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance",
      "coverage_count": 1,
      "days_ago": 3,
      "recency_weight": 0.8772170375657401,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2972
      },
      "impact_horizon_weight": 0.9123,
      "final_weight": 0.8946
    },
    {
      "title": "Evers announces $100 million tax credits deal with Eli Lilly for Kenosha County development",
      "url": "https://finnhub.io/api/news?id=12675377918088399543e946c3cd8af70c3a7de7b5ab4a72e8ff8d006bcd1b5c",
      "sourceurl": "https://finnhub.io/api/news?id=12675377918088399543e946c3cd8af70c3a7de7b5ab4a72e8ff8d006bcd1b5c",
      "seendate": "20250805T160259Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in performance-based tax credits.",
      "coverage_count": 1,
      "days_ago": 3,
      "recency_weight": 0.8772170375657401,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2801
      },
      "impact_horizon_weight": 0.9123,
      "final_weight": 0.8946
    },
    {
      "title": "Health Care Down After Eli Lilly Earnings -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=35d50ceb653c52ef969a80f9472a9128440bd015c2f91f357d99d66fd21b730d",
      "sourceurl": "https://finnhub.io/api/news?id=35d50ceb653c52ef969a80f9472a9128440bd015c2f91f357d99d66fd21b730d",
      "seendate": "20250807T175300Z",
      "domain": "MarketWatch",
      "language": "English",
      "content": "Health Care Down After Eli Lilly Earnings -- Health Care Roundup",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.3758
      },
      "impact_horizon_weight": 0.7748,
      "final_weight": 0.8612
    },
    {
      "title": "Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying",
      "url": "https://finnhub.io/api/news?id=caecb6949683ec8e92e01bbf681ed85e9db57d8a20394ddadc05e5862b7d3724",
      "sourceurl": "https://finnhub.io/api/news?id=caecb6949683ec8e92e01bbf681ed85e9db57d8a20394ddadc05e5862b7d3724",
      "seendate": "20250807T141933Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.2977
      },
      "impact_horizon_weight": 0.7748,
      "final_weight": 0.8612
    },
    {
      "title": "Stock Market Today: Dow Futures Rise On Trump Tariff News; Apple, Nvidia Rally, Eli Lilly Plunges (Live Coverage)",
      "url": "https://finnhub.io/api/news?id=bb5b565d20087c9bace1fd2cb243104a7a58aff768b83da6db71aebddf693324",
      "sourceurl": "https://finnhub.io/api/news?id=bb5b565d20087c9bace1fd2cb243104a7a58aff768b83da6db71aebddf693324",
      "seendate": "20250807T130704Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "The Dow Jones Index rose Thursday on Trump tariff news. Eli Lilly plunged on disappointing weight-loss drug trial results.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.3232
      },
      "impact_horizon_weight": 0.7748,
      "final_weight": 0.8612
    },
    {
      "title": "Novo Nordisk shares jump as Eli Lilly obesity pill disappoints",
      "url": "https://finnhub.io/api/news?id=5dbc030e0ead837bfec899cd94650d16d3ab8d0169024d55892c95a3ec8b6252",
      "sourceurl": "https://finnhub.io/api/news?id=5dbc030e0ead837bfec899cd94650d16d3ab8d0169024d55892c95a3ec8b6252",
      "seendate": "20250807T121718Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Investing.com -- Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug orforglipron underwhelmed investors, prompting concerns over both efficacy and tolerability.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.4119
      },
      "impact_horizon_weight": 0.7748,
      "final_weight": 0.8612
    },
    {
      "title": "Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints",
      "url": "https://finnhub.io/api/news?id=dea0071646028a18eb1fc257e16e54ed9869dfa103494cf78473b4a3167725d3",
      "sourceurl": "https://finnhub.io/api/news?id=dea0071646028a18eb1fc257e16e54ed9869dfa103494cf78473b4a3167725d3",
      "seendate": "20250807T115015Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "(Reuters) -Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-leading obesity treatment. The market had anticipated Eli Lilly's orforglipron pill to become a strong competitor to Novo's weight-loss drugs, Kepler Cheuvreux analyst David Evans said in an emailed comment.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.4024
      },
      "impact_horizon_weight": 0.7748,
      "final_weight": 0.8612
    },
    {
      "title": "Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors",
      "url": "https://finnhub.io/api/news?id=b9096f025c235f6531535b0d739efdc9d097c132b3918ec5067763c0a1672c23",
      "sourceurl": "https://finnhub.io/api/news?id=b9096f025c235f6531535b0d739efdc9d097c132b3918ec5067763c0a1672c23",
      "seendate": "20250807T095546Z",
      "domain": "Benzinga",
      "language": "English",
      "content": "Eli Lilly&#39;s obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.2743
      },
      "impact_horizon_weight": 0.7748,
      "final_weight": 0.8612
    },
    {
      "title": "Eli Lilly: The Worst May Be Already Over (Earnings Preview)",
      "url": "https://finnhub.io/api/news?id=a889660edab9d8e2c127c12fae5128f27512e693e3627d5adaa3c25e6ec007e4",
      "sourceurl": "https://finnhub.io/api/news?id=a889660edab9d8e2c127c12fae5128f27512e693e3627d5adaa3c25e6ec007e4",
      "seendate": "20250801T080000Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.",
      "coverage_count": 1,
      "days_ago": 7,
      "recency_weight": 0.7366306788530732,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "MEDIUM_TERM",
        "horizon_days": 14,
        "confidence": 0.2989
      },
      "impact_horizon_weight": 1.0,
      "final_weight": 0.8583
    },
    {
      "title": "Eli Lilly stock drops after Trump unleashes 250% pharma tariff warning",
      "url": "https://finnhub.io/api/news?id=83241685863c1e20a711364e4c9f500cc4119547ac516f33ab08ca016bf2a714",
      "sourceurl": "https://finnhub.io/api/news?id=83241685863c1e20a711364e4c9f500cc4119547ac516f33ab08ca016bf2a714",
      "seendate": "20250805T191612Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Trump tariff shock hits Eli Lilly as $27B U.S. plan fails to impress",
      "coverage_count": 1,
      "days_ago": 3,
      "recency_weight": 0.8772170375657401,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.4546
      },
      "impact_horizon_weight": 0.6065,
      "final_weight": 0.7294
    },
    {
      "title": "Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed",
      "url": "https://finnhub.io/api/news?id=0b53835e2db32e482232b9d1b5490145fae24f9b17cdc04b2d87331cd89ca14a",
      "sourceurl": "https://finnhub.io/api/news?id=0b53835e2db32e482232b9d1b5490145fae24f9b17cdc04b2d87331cd89ca14a",
      "seendate": "20250801T174750Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive announcements, the company's share price fell by 4.62% over the past month. In contrast, Lilly's progress in diabetes and Alzheimer's treatments...",
      "coverage_count": 1,
      "days_ago": 7,
      "recency_weight": 0.7366306788530732,
      "content_stats": {
        "total_sentences": 4,
        "relevant_sentences": 3,
        "relevance_ratio": 0.75,
        "condensed": false,
        "filter_action": "filtered"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3433
      },
      "impact_horizon_weight": 0.6065,
      "final_weight": 0.6684
    },
    {
      "title": "Trim Your AI Stocks And Buy Eli Lilly",
      "url": "https://finnhub.io/api/news?id=8720f062a519f38c9a63ab1ca038f5ac886077cab33af49ed0850682d8bb1de9",
      "sourceurl": "https://finnhub.io/api/news?id=8720f062a519f38c9a63ab1ca038f5ac886077cab33af49ed0850682d8bb1de9",
      "seendate": "20250801T151819Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click for my LLY stock update.",
      "coverage_count": 1,
      "days_ago": 7,
      "recency_weight": 0.7366306788530732,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.342
      },
      "impact_horizon_weight": 0.6065,
      "final_weight": 0.6684
    },
    {
      "title": "Eli Lilly: The Best Growth Prospects Come At A Price",
      "url": "https://finnhub.io/api/news?id=a103bea0a7385c6e454f3842fe118b732b1d0bb2629309292d9913da91a5cfde",
      "sourceurl": "https://finnhub.io/api/news?id=a103bea0a7385c6e454f3842fe118b732b1d0bb2629309292d9913da91a5cfde",
      "seendate": "20250801T124116Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs suggest caution. Click here to read.",
      "coverage_count": 1,
      "days_ago": 7,
      "recency_weight": 0.7366306788530732,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2926
      },
      "impact_horizon_weight": 0.6065,
      "final_weight": 0.6684
    },
    {
      "title": "Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed",
      "url": "https://finnhub.io/api/news?id=e22182e31a15ea6c3ef03fe0df6aded18481a984f4c6c4644ff70b2ae65b589e",
      "sourceurl": "https://finnhub.io/api/news?id=e22182e31a15ea6c3ef03fe0df6aded18481a984f4c6c4644ff70b2ae65b589e",
      "seendate": "20250801T114116Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.",
      "coverage_count": 1,
      "days_ago": 7,
      "recency_weight": 0.7366306788530732,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.33
      },
      "impact_horizon_weight": 0.6065,
      "final_weight": 0.6684
    },
    {
      "title": "Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer",
      "url": "https://finnhub.io/api/news?id=78e32c638620e5bcfba032443c837bbeb4074b18e64369dd2d45f414b3472b2b",
      "sourceurl": "https://finnhub.io/api/news?id=78e32c638620e5bcfba032443c837bbeb4074b18e64369dd2d45f414b3472b2b",
      "seendate": "20250731T195450Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date. Yet, despite the stock’s […]",
      "coverage_count": 1,
      "days_ago": 8,
      "recency_weight": 0.7051564589384418,
      "content_stats": {
        "total_sentences": 4,
        "relevant_sentences": 4,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3975
      },
      "impact_horizon_weight": 0.5205,
      "final_weight": 0.6058
    },
    {
      "title": "Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results",
      "url": "https://finnhub.io/api/news?id=43f35e65f9e32291f7407dbf9092e4d017018be2561b238728eb3144dbcd827f",
      "sourceurl": "https://finnhub.io/api/news?id=43f35e65f9e32291f7407dbf9092e4d017018be2561b238728eb3144dbcd827f",
      "seendate": "20250731T174033Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with Mounjaro and Kisunla in cardiovascular health and Alzheimer's treatment, respectively. Over the past month, LLY experienced a 2.5% decline in its stock price, slightly diverging from broader market trends where major indexes were generally buoyed by strong earnings from tech giants like Microsoft and Meta. While Eli Lilly's advancements in clinical trials and strategic...",
      "coverage_count": 1,
      "days_ago": 8,
      "recency_weight": 0.7051564589384418,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.4131
      },
      "impact_horizon_weight": 0.5205,
      "final_weight": 0.6058
    },
    {
      "title": "Eli Lilly and Company (LLY): Jim Cramer’s “Bullish” On News Of Tariffs",
      "url": "https://finnhub.io/api/news?id=ec5cbc07855d0332568210b79bf6655acd7aefc9b94b4a01a7e690edea34e13f",
      "sourceurl": "https://finnhub.io/api/news?id=ec5cbc07855d0332568210b79bf6655acd7aefc9b94b4a01a7e690edea34e13f",
      "seendate": "20250730T190243Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top pharmaceutical stocks. While the firm’s weight loss drugs are one reason the CNBC TV host likes it, he’s also bullish on […]",
      "coverage_count": 1,
      "days_ago": 9,
      "recency_weight": 0.6750270466019812,
      "content_stats": {
        "total_sentences": 4,
        "relevant_sentences": 4,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3813
      },
      "impact_horizon_weight": 0.4376,
      "final_weight": 0.5435
    },
    {
      "title": "Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration",
      "url": "https://finnhub.io/api/news?id=a709ce61ce3e7f305d93c3a0555f57171f9fa9005e9ffcd34b8ade39713452e5",
      "sourceurl": "https://finnhub.io/api/news?id=a709ce61ce3e7f305d93c3a0555f57171f9fa9005e9ffcd34b8ade39713452e5",
      "seendate": "20250730T173739Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product results and collaborations indicate a commitment to innovation in Alzheimer's and blood cancer treatments. The continuous advancements with Kisunla and Jaypirca, alongside partnerships like the one with LTZ Therapeutics, highlight the company’s focused push towards addressing significant medical needs. Despite these positive developments, Eli Lilly's stock saw a 1.61%...",
      "coverage_count": 1,
      "days_ago": 9,
      "recency_weight": 0.6750270466019812,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.4313
      },
      "impact_horizon_weight": 0.4376,
      "final_weight": 0.5435
    },
    {
      "title": "Eli Lilly (LLY) Declines More Than Market: Some Information for Investors",
      "url": "https://finnhub.io/api/news?id=41cf4a8e76de290acba48c859d9a6b8a2c46c1185246bd2b48aa0c46bfb5dba7",
      "sourceurl": "https://finnhub.io/api/news?id=41cf4a8e76de290acba48c859d9a6b8a2c46c1185246bd2b48aa0c46bfb5dba7",
      "seendate": "20250729T214502Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.",
      "coverage_count": 1,
      "days_ago": 10,
      "recency_weight": 0.6461849818835329,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3641
      },
      "impact_horizon_weight": 0.3604,
      "final_weight": 0.4826
    },
    {
      "title": "Why Eli Lilly (LLY) Stock Is Falling Today",
      "url": "https://finnhub.io/api/news?id=e0f47ea9ec553d05d05a9454b77158363bede976c769f203a7ed1ad51fa132f4",
      "sourceurl": "https://finnhub.io/api/news?id=e0f47ea9ec553d05d05a9454b77158363bede976c769f203a7ed1ad51fa132f4",
      "seendate": "20250729T182615Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the weight-loss drug market, Novo Nordisk, lowered its sales and profit growth forecasts for 2025. The lowered guidance from the Danish pharmaceutical giant cast a shadow over the high-growth weight-loss drug sector. This was the second time this year Novo Nordisk had reduced its outlook, which amplified investor concerns about the market's future performance. Compounding the",
      "coverage_count": 1,
      "days_ago": 10,
      "recency_weight": 0.6461849818835329,
      "content_stats": {
        "total_sentences": 4,
        "relevant_sentences": 4,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3774
      },
      "impact_horizon_weight": 0.3604,
      "final_weight": 0.4826
    },
    {
      "title": "Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card",
      "url": "https://finnhub.io/api/news?id=353a8754978f3e8d836db02110035f00978e372529a1be2f9ef61eac6abaa409",
      "sourceurl": "https://finnhub.io/api/news?id=353a8754978f3e8d836db02110035f00978e372529a1be2f9ef61eac6abaa409",
      "seendate": "20250729T161419Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Julie Hyman outlines some of the top market stories as part of today's Market Minute. Nvidia (NVDA) reportedly placed an order for 300,000 H20 chipsets with Taiwan Semiconductor Manufacturing Company (TSM) in preparation to sell in China, according to reporting from Reuters. Eli Lilly (LLY) shares fall as Novo Nordisk (NVO) stock plummets amid fears about the weight-loss drug boom slowing. JPMorgan (JPM) is reportedly in talks with Apple (AAPL) to take over the iPhone maker's credit card business from Goldman Sachs (GS), according to a report from The Wall Street Journal. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "coverage_count": 1,
      "days_ago": 10,
      "recency_weight": 0.6461849818835329,
      "content_stats": {
        "total_sentences": 5,
        "relevant_sentences": 5,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2879
      },
      "impact_horizon_weight": 0.3604,
      "final_weight": 0.4826
    },
    {
      "title": "Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer’s Trial Results, Says BMO Capital",
      "url": "https://finnhub.io/api/news?id=92622eecbae3a6ebdf6409aa75072c733f454112859969c3f519d0b95fa8fcc7",
      "sourceurl": "https://finnhub.io/api/news?id=92622eecbae3a6ebdf6409aa75072c733f454112859969c3f519d0b95fa8fcc7",
      "seendate": "20250729T053717Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company (NYSE:LLY). According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the […]",
      "coverage_count": 1,
      "days_ago": 10,
      "recency_weight": 0.6461849818835329,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3964
      },
      "impact_horizon_weight": 0.3604,
      "final_weight": 0.4826
    },
    {
      "title": "Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron",
      "url": "https://finnhub.io/api/news?id=c2d7d45bac0e4bd2b892174ff3af985c35b332efccf93dc8472bb087fdc310c9",
      "sourceurl": "https://finnhub.io/api/news?id=c2d7d45bac0e4bd2b892174ff3af985c35b332efccf93dc8472bb087fdc310c9",
      "seendate": "20250729T052939Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company (NYSE:LLY) announced new Phase 3 trial results for Orforglipron, which is an oral drug for adults with type 2 diabetes. This comes as a breakthrough for the company as Orforglipron is the first […]",
      "coverage_count": 1,
      "days_ago": 10,
      "recency_weight": 0.6461849818835329,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.2582
      },
      "impact_horizon_weight": 0.3604,
      "final_weight": 0.4826
    },
    {
      "title": "Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage",
      "url": "https://finnhub.io/api/news?id=9e9ff092323b8c541c9031ee94ecd9454b54930a50ec8fc33dd58cbb61df87d0",
      "sourceurl": "https://finnhub.io/api/news?id=9e9ff092323b8c541c9031ee94ecd9454b54930a50ec8fc33dd58cbb61df87d0",
      "seendate": "20250801T123241Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with covering weight loss drugs.",
      "coverage_count": 1,
      "days_ago": 7,
      "recency_weight": 0.7366306788530732,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.2882
      },
      "impact_horizon_weight": 0.2909,
      "final_weight": 0.4629
    },
    {
      "title": "Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY)",
      "url": "https://finnhub.io/api/news?id=3ea17e31f7f44d2830604ae3a7685fce1044f6ecde84dd438364288616d7d451",
      "sourceurl": "https://finnhub.io/api/news?id=3ea17e31f7f44d2830604ae3a7685fce1044f6ecde84dd438364288616d7d451",
      "seendate": "20250728T201223Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s GLP-1 oral medication Orforglipron could […]",
      "coverage_count": 1,
      "days_ago": 11,
      "recency_weight": 0.6185752599303274,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.3854
      },
      "impact_horizon_weight": 0.2909,
      "final_weight": 0.4242
    },
    {
      "title": "Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales",
      "url": "https://finnhub.io/api/news?id=84a7e5e918208320900d011de5089518ca2da0bb149ccef3e5a7c28b4714fa78",
      "sourceurl": "https://finnhub.io/api/news?id=84a7e5e918208320900d011de5089518ca2da0bb149ccef3e5a7c28b4714fa78",
      "seendate": "20250728T054155Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company (NYSE:LLY) ahead of the company’s second-quarter earnings report and increased its price target from $936 to $942. In contrast to the consensus predictions of $4.39 […]",
      "coverage_count": 1,
      "days_ago": 11,
      "recency_weight": 0.6185752599303274,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "SHORT_TERM",
        "horizon_days": 7,
        "confidence": 0.5059
      },
      "impact_horizon_weight": 0.2909,
      "final_weight": 0.4242
    },
    {
      "title": "Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing",
      "url": "https://finnhub.io/api/news?id=ee25f6a7ccf490a1c8ac7a7c36dbd53233365d252df20a9a81eca58f039ed2f5",
      "sourceurl": "https://finnhub.io/api/news?id=ee25f6a7ccf490a1c8ac7a7c36dbd53233365d252df20a9a81eca58f039ed2f5",
      "seendate": "20250731T135324Z",
      "domain": "MarketWatch",
      "language": "English",
      "content": "Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing",
      "coverage_count": 1,
      "days_ago": 8,
      "recency_weight": 0.7051564589384418,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "IMMEDIATE",
        "horizon_days": 3,
        "confidence": 0.2928
      },
      "impact_horizon_weight": 0.2301,
      "final_weight": 0.4028
    },
    {
      "title": "Morgan Stanley Remains Bullish on Eli Lilly (LLY)",
      "url": "https://finnhub.io/api/news?id=6246cbba4b9cf984f3c79a3dff46a851e556e459e6aad6353bde01516dec5b21",
      "sourceurl": "https://finnhub.io/api/news?id=6246cbba4b9cf984f3c79a3dff46a851e556e459e6aad6353bde01516dec5b21",
      "seendate": "20250728T060759Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly and Company (NYSE:LLY), raising the target price from $1,133 to $1,135. On July 9, Eli Lilly and Company (NYSE:LLY) announced that the US […]",
      "coverage_count": 1,
      "days_ago": 11,
      "recency_weight": 0.6185752599303274,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "LONG_TERM",
        "horizon_days": 31,
        "confidence": 0.2843
      },
      "impact_horizon_weight": 0.1783,
      "final_weight": 0.3321
    },
    {
      "title": "Eli Lilly (LLY) Announces Positive Results For Jaypirca In Phase 3 Trial",
      "url": "https://finnhub.io/api/news?id=2f87e90218bfe2679112897fc1ed1d9a238461a711c95c69e93971e8fbada2ec",
      "sourceurl": "https://finnhub.io/api/news?id=2f87e90218bfe2679112897fc1ed1d9a238461a711c95c69e93971e8fbada2ec",
      "seendate": "20250729T173223Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia. The company's 6% share price increase over the past week may have been influenced by investor optimism surrounding these findings, aligning with general market trends which saw the S&P 500 and Nasdaq reach new highs. While broader market dynamics favor strong corporate earnings and positive...",
      "coverage_count": 1,
      "days_ago": 10,
      "recency_weight": 0.6461849818835329,
      "content_stats": {
        "total_sentences": 3,
        "relevant_sentences": 3,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "LONG_TERM",
        "horizon_days": 31,
        "confidence": 0.321
      },
      "impact_horizon_weight": 0.1353,
      "final_weight": 0.2957
    },
    {
      "title": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
      "url": "https://finnhub.io/api/news?id=44247ebe19dea9f5a0c21858a137dc32ed132fbc81d573c575182eef76c1c4a8",
      "sourceurl": "https://finnhub.io/api/news?id=44247ebe19dea9f5a0c21858a137dc32ed132fbc81d573c575182eef76c1c4a8",
      "seendate": "20250731T140024Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "coverage_count": 1,
      "days_ago": 8,
      "recency_weight": 0.7051564589384418,
      "content_stats": {
        "total_sentences": 2,
        "relevant_sentences": 2,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "LONG_TERM",
        "horizon_days": 31,
        "confidence": 0.3261
      },
      "impact_horizon_weight": 0.0734,
      "final_weight": 0.2275
    },
    {
      "title": "Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics",
      "url": "https://finnhub.io/api/news?id=25b916d5163fb6047eaa1861705477413fd1481635df9a6e4780c2af74105e77",
      "sourceurl": "https://finnhub.io/api/news?id=25b916d5163fb6047eaa1861705477413fd1481635df9a6e4780c2af74105e77",
      "seendate": "20250804T131510Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
      "coverage_count": 1,
      "days_ago": 4,
      "recency_weight": 0.8397359459606585,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "LONG_TERM",
        "horizon_days": 31,
        "confidence": 0.3326
      },
      "impact_horizon_weight": 0.0169,
      "final_weight": 0.1191
    },
    {
      "title": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings",
      "url": "https://finnhub.io/api/news?id=5125068695585372431917e08263550e33ac68ada198098e44b97f7d2449ee3d",
      "sourceurl": "https://finnhub.io/api/news?id=5125068695585372431917e08263550e33ac68ada198098e44b97f7d2449ee3d",
      "seendate": "20250806T114144Z",
      "domain": "Yahoo",
      "language": "English",
      "content": "Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly earnings at $5.59 per share, up from $3.92 per share in the year-ago period. Eli Lilly projects to report quarterly revenue of $14.67 billion, compared to $11.3 billion a year earlier, according to data from Benzinga Pro. With the recent buzz around Eli Lilly, some investors may be eyeing potential gains fro",
      "coverage_count": 1,
      "days_ago": 2,
      "recency_weight": 0.9163710743801653,
      "content_stats": {
        "total_sentences": 5,
        "relevant_sentences": 5,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "LONG_TERM",
        "horizon_days": 31,
        "confidence": 0.3309
      },
      "impact_horizon_weight": 0.0072,
      "final_weight": 0.081
    },
    {
      "title": "Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript",
      "url": "https://finnhub.io/api/news?id=2b57a4a5f6efdaa7d384d4e83e29822c1078897232b00bc0ba5420ef14ad924a",
      "sourceurl": "https://finnhub.io/api/news?id=2b57a4a5f6efdaa7d384d4e83e29822c1078897232b00bc0ba5420ef14ad924a",
      "seendate": "20250807T122819Z",
      "domain": "SeekingAlpha",
      "language": "English",
      "content": "Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ETCompany ParticipantsDaniel M.",
      "coverage_count": 1,
      "days_ago": 1,
      "recency_weight": 0.9572727272727273,
      "content_stats": {
        "total_sentences": 1,
        "relevant_sentences": 1,
        "relevance_ratio": 1.0,
        "condensed": false,
        "filter_action": "no_change"
      },
      "impact_horizon": {
        "category": "LONG_TERM",
        "horizon_days": 31,
        "confidence": 0.2997
      },
      "impact_horizon_weight": 0.0045,
      "final_weight": 0.0658
    }
  ]
}